Journal of NeuroVirology

, Volume 17, Issue 3, pp 288–290

Natalizumab and HSV meningitis

Authors

    • Division of Infectious DiseasesMassachusetts General Hospital
    • Harvard Medical School
  • Eleftherios Mylonakis
    • Division of Infectious DiseasesMassachusetts General Hospital
    • Harvard Medical School
  • Rocio M. Hurtado
    • Division of Infectious DiseasesMassachusetts General Hospital
    • Harvard Medical School
  • Nagagopal Venna
    • Department of NeurologyMassachusetts General Hospital
Case Report

DOI: 10.1007/s13365-011-0027-4

Cite this article as:
Shenoy, E.S., Mylonakis, E., Hurtado, R.M. et al. J. Neurovirol. (2011) 17: 288. doi:10.1007/s13365-011-0027-4

Abstract

Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) is a monoclonal antibody approved for use in patients with relapsing multiple sclerosis (MS) as well as moderate to severe Crohn’s disease. We report the first case of a patient with a history of MS, on monthly natalizumab, who developed HSV-2 meningitis. We discuss the mechanism of action of natalizumab and review what is known about the reactivation of herpes infection in association with this medication. The question of herpes simplex virus (HSV) and varicella zoster virus (VZV) prophylaxis for patients is raised.

Copyright information

© Journal of NeuroVirology, Inc. 2011